Cargando…
Establishment of lung cancer patient-derived xenograft models and primary cell lines for lung cancer study
BACKGROUND: The overall 5-year survival rate of lung cancer is about 15% even with therapeutic drugs like tyrosine kinase inhibitors. Ideal models are urgently needed for exploring mechanisms and finding new drugs. Patient-derived xenografts (PDX) models and primary cells are both used to screen the...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5964929/ https://www.ncbi.nlm.nih.gov/pubmed/29788985 http://dx.doi.org/10.1186/s12967-018-1516-5 |
_version_ | 1783325271532765184 |
---|---|
author | Jiang, Yanan Zhao, Jimin Zhang, Yi Li, Ke Li, Tiepeng Chen, Xinhuan Zhao, Simin Zhao, Song Liu, Kangdong Dong, Ziming |
author_facet | Jiang, Yanan Zhao, Jimin Zhang, Yi Li, Ke Li, Tiepeng Chen, Xinhuan Zhao, Simin Zhao, Song Liu, Kangdong Dong, Ziming |
author_sort | Jiang, Yanan |
collection | PubMed |
description | BACKGROUND: The overall 5-year survival rate of lung cancer is about 15% even with therapeutic drugs like tyrosine kinase inhibitors. Ideal models are urgently needed for exploring mechanisms and finding new drugs. Patient-derived xenografts (PDX) models and primary cells are both used to screen therapeutic regimens for cancer. However, PDX models and primary cells from the same patient are difficult to establish. Their consistency to the original tumor tissue is not well studied. METHODS: 31 lung cancer patient tissues were procured to establish the lung cancer PDX models and primary cell lines. Tumor growth measurements, histological and immunohistochemistry analysis, Western blotting, EGFR and K-RAS mutation detection and gefitinib sensitive assay were performed to evaluate the characteristic of established PDX models. Immunofluorescence analysis, anchorage-independent cell growth, Western blotting and gefitinib sensitive assay were performed to assay the characteristic of established primary cell lines. The whole-exome sequencing was used to compare the characteristic of the patient’s tumor tissue, established PDX and primary cell line. RESULTS: Twenty-one lung cancer PDX models (67.74%, 21/31) and ten primary cell lines (32.25%, 10/31) were established from patients’ tumor tissues. The histology and pathological immunohistochemistry of PDX xenografts are consistent with the patients’ tumor samples. Various signal pathways were activated in different PDX models (n = 5) and primary cell lines (n = 2). EGFR mutation PDX model and primary cell line (LG1) were sensitive to gefitinib treatment. The expression of CK8/18, TTF1 and NapsinA in LG1 and LG50 primary cells were also positive. And the activated signal pathways were activated in LG1 and LG50 primary cell lines. Furthermore, the gene mutation in PDX tumor tissues and primary cell line (LG50) was consistent with the mutation in LG50 patient’s tumor tissues. CONCLUSION: These data suggested that established lung cancer PDX models and primary cell lines reserved mostly molecular characteristics of primary lung cancer and could provide a new tool to further understand the mechanisms and explore new therapeutic strategies. |
format | Online Article Text |
id | pubmed-5964929 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-59649292018-05-24 Establishment of lung cancer patient-derived xenograft models and primary cell lines for lung cancer study Jiang, Yanan Zhao, Jimin Zhang, Yi Li, Ke Li, Tiepeng Chen, Xinhuan Zhao, Simin Zhao, Song Liu, Kangdong Dong, Ziming J Transl Med Research BACKGROUND: The overall 5-year survival rate of lung cancer is about 15% even with therapeutic drugs like tyrosine kinase inhibitors. Ideal models are urgently needed for exploring mechanisms and finding new drugs. Patient-derived xenografts (PDX) models and primary cells are both used to screen therapeutic regimens for cancer. However, PDX models and primary cells from the same patient are difficult to establish. Their consistency to the original tumor tissue is not well studied. METHODS: 31 lung cancer patient tissues were procured to establish the lung cancer PDX models and primary cell lines. Tumor growth measurements, histological and immunohistochemistry analysis, Western blotting, EGFR and K-RAS mutation detection and gefitinib sensitive assay were performed to evaluate the characteristic of established PDX models. Immunofluorescence analysis, anchorage-independent cell growth, Western blotting and gefitinib sensitive assay were performed to assay the characteristic of established primary cell lines. The whole-exome sequencing was used to compare the characteristic of the patient’s tumor tissue, established PDX and primary cell line. RESULTS: Twenty-one lung cancer PDX models (67.74%, 21/31) and ten primary cell lines (32.25%, 10/31) were established from patients’ tumor tissues. The histology and pathological immunohistochemistry of PDX xenografts are consistent with the patients’ tumor samples. Various signal pathways were activated in different PDX models (n = 5) and primary cell lines (n = 2). EGFR mutation PDX model and primary cell line (LG1) were sensitive to gefitinib treatment. The expression of CK8/18, TTF1 and NapsinA in LG1 and LG50 primary cells were also positive. And the activated signal pathways were activated in LG1 and LG50 primary cell lines. Furthermore, the gene mutation in PDX tumor tissues and primary cell line (LG50) was consistent with the mutation in LG50 patient’s tumor tissues. CONCLUSION: These data suggested that established lung cancer PDX models and primary cell lines reserved mostly molecular characteristics of primary lung cancer and could provide a new tool to further understand the mechanisms and explore new therapeutic strategies. BioMed Central 2018-05-22 /pmc/articles/PMC5964929/ /pubmed/29788985 http://dx.doi.org/10.1186/s12967-018-1516-5 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Jiang, Yanan Zhao, Jimin Zhang, Yi Li, Ke Li, Tiepeng Chen, Xinhuan Zhao, Simin Zhao, Song Liu, Kangdong Dong, Ziming Establishment of lung cancer patient-derived xenograft models and primary cell lines for lung cancer study |
title | Establishment of lung cancer patient-derived xenograft models and primary cell lines for lung cancer study |
title_full | Establishment of lung cancer patient-derived xenograft models and primary cell lines for lung cancer study |
title_fullStr | Establishment of lung cancer patient-derived xenograft models and primary cell lines for lung cancer study |
title_full_unstemmed | Establishment of lung cancer patient-derived xenograft models and primary cell lines for lung cancer study |
title_short | Establishment of lung cancer patient-derived xenograft models and primary cell lines for lung cancer study |
title_sort | establishment of lung cancer patient-derived xenograft models and primary cell lines for lung cancer study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5964929/ https://www.ncbi.nlm.nih.gov/pubmed/29788985 http://dx.doi.org/10.1186/s12967-018-1516-5 |
work_keys_str_mv | AT jiangyanan establishmentoflungcancerpatientderivedxenograftmodelsandprimarycelllinesforlungcancerstudy AT zhaojimin establishmentoflungcancerpatientderivedxenograftmodelsandprimarycelllinesforlungcancerstudy AT zhangyi establishmentoflungcancerpatientderivedxenograftmodelsandprimarycelllinesforlungcancerstudy AT like establishmentoflungcancerpatientderivedxenograftmodelsandprimarycelllinesforlungcancerstudy AT litiepeng establishmentoflungcancerpatientderivedxenograftmodelsandprimarycelllinesforlungcancerstudy AT chenxinhuan establishmentoflungcancerpatientderivedxenograftmodelsandprimarycelllinesforlungcancerstudy AT zhaosimin establishmentoflungcancerpatientderivedxenograftmodelsandprimarycelllinesforlungcancerstudy AT zhaosong establishmentoflungcancerpatientderivedxenograftmodelsandprimarycelllinesforlungcancerstudy AT liukangdong establishmentoflungcancerpatientderivedxenograftmodelsandprimarycelllinesforlungcancerstudy AT dongziming establishmentoflungcancerpatientderivedxenograftmodelsandprimarycelllinesforlungcancerstudy |